# A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)

> **NCT04855747** · PHASE3 · TERMINATED · sponsor: **Levomecor Inc.** · enrollment: 236 (actual)

## Conditions studied

- Major Depressive Disorder
- Depression

## Interventions

- **DRUG:** REL-1017
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04855747
- **Lead sponsor:** Levomecor Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-30
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-01-14
- **Target enrollment:** 236 (ACTUAL)
- **Why stopped:** Program Discontinued
- **Last updated:** 2025-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04855747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04855747, "A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04855747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*